HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Wins Second Landmark German Case, This Time For Probiotics

Executive Summary

Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.

You may also be interested in...



Novartis Seeks 'Amicable' Resolution Of German Probiotics Dispute

Novartis is in discussion via its Hexal subsidiary with Germany's Association for Social Competition (VSW) over whether it must withdraw its Biosan range of probiotic supplements currently on the German market following a recent Higher Regional Court ruling. 

German Wellness Market News: Dr Loges Ignores EU CBD Rules, Three ‘Noo’ Brain Health Supplements

A new CBD oil from Dr Loges, three ‘nootropic’ brain health supplements from Dr Loges, Hevert and Pure Encapsulations and a magnesium supplement from Stada feature in this month’s German wellness market round-up.

Novartis Wins Landmark Case Against German Government Over Desloratadine Switch

Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel